ORGO
Organogenesis Holdings Inc. Healthcare - Drug Manufacturers - Specialty & Generic Investor Relations →
Organogenesis Holdings Inc. (ORGO) closed at $2.39 as of 2026-03-20, trading 31.9% below its 200-week moving average of $3.51. This places ORGO in the extreme value zone. The stock is currently moving closer to the line, down from -25.1% last week. With a 14-week RSI of 25, ORGO is in oversold territory.
Trading volume is running at 1.0x of its 14-week average, which is in the normal range. The balance between buying and selling volume (1.07 ratio) is neutral — neither side is clearly dominating.
Over the past 432 weeks of data, ORGO has crossed below its 200-week moving average 7 times. On average, these episodes lasted 43 weeks. The average one-year return after crossing below was -30.8%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $307 million, ORGO is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at 9.0%. The stock trades at 1.0x book value.
Over the past 8.3 years, a hypothetical investment of $100 in ORGO would have grown to $24, compared to $278 for the S&P 500. ORGO has returned -15.7% annualized vs 13.0% for the index, underperforming the broader market over this period.
In the past 12 months, corporate insiders have made 4 open-market purchases totaling $1,861,422. Notably, these purchases occurred while ORGO is trading below its 200-week moving average — insiders are buying when the market is most pessimistic.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: ORGO vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After ORGO Crosses Below the Line?
Across 6 historical episodes, buying ORGO when it crossed below its 200-week moving average produced an average return of -32.3% after 12 months (median -26.0%), compared to +4.3% for the S&P 500 over the same periods. 17% of those episodes were profitable after one year. After 24 months, the average return was -34.3% vs +20.3% for the index.
Each line shows $100 invested at the moment ORGO crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
ORGO has crossed below its 200-week MA 7 times with an average 1-year return of +-30.8% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Dec 2017 | Dec 2017 | 2 | 0.6% | +3.3% | -75.7% |
| Feb 2018 | Mar 2018 | 3 | 0.0% | -20.8% | -75.9% |
| Apr 2018 | Apr 2018 | 1 | 0.1% | -14.8% | -75.9% |
| Oct 2018 | Oct 2018 | 1 | 1.5% | -27.0% | -75.6% |
| Feb 2019 | Jan 2021 | 101 | 69.2% | -54.0% | -76.6% |
| Nov 2021 | Jul 2025 | 189 | 74.5% | -71.5% | -74.9% |
| Feb 2026 | Ongoing | 4+ | 31.9% | Ongoing | -25.5% |
| Average | 43 | — | +-30.8% | — |
Frequently Asked Questions
Is ORGO below its 200-week moving average?
Yes. As of 2026-03-20, Organogenesis Holdings Inc. (ORGO) is trading 31.9% below its 200-week moving average of $3.51. The current price is $2.39.
What is ORGO's 200-week moving average price?
Organogenesis Holdings Inc.'s 200-week moving average is $3.51 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when ORGO drops below its 200-week moving average?
ORGO has crossed below its 200-week moving average 7 times in our data. The average one-year return after these crossings was -30.8%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 43 weeks on average.
Is ORGO a good value right now?
Here's what our data says about ORGO as of 2026-03-20: The stock is below its 200-week moving average, which is the starting point for our analysis. The 14-week RSI is 25 (oversold). Free cash flow is currently negative. Return on equity is 9.0%. Price-to-book is 1.0x. This is not a buy or sell recommendation — always do your own research.
How does ORGO compare to the S&P 500?
Over the past 8.3 years, $100 invested in ORGO would have grown to $24, compared to $278 for the S&P 500. That's -15.7% annualized vs 13.0% for the index. ORGO has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20